Free tool
FAERS Monitor: Xerava
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211109 or its brand name (Xerava, Eravacycline Dihydrochloride). Reports on generic versions are filed under their own applications.
Reports
298
Serious
227
76% of reports
Hospitalization
85
Death reported
50
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use98
- drug ineffective33
- blood fibrinogen decreased29
- thrombocytopenia18
- nausea15
- product use in unapproved indication15
- diarrhoea14
- multiple organ dysfunction syndrome14
- condition aggravated12
- coagulopathy11
- hypofibrinogenaemia11
- lactic acidosis11
- pancreatitis11
- drug intolerance10
- hypertransaminasaemia10
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 12 |
| 2020 | 10 |
| 2021 | 15 |
| 2022 | 29 |
| 2023 | 52 |
| 2024 | 41 |
| 2025 | 45 |
| 2026 | 94 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,861 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood fibrinogen decreasedSignal | 29 | 1840.8 | 1296.2 | 50,198 |
| hypofibrinogenaemiaSignal | 11 | 792.2 | 442.1 | 7,832 |
| hypertransaminasaemiaSignal | 10 | 101.6 | 55.2 | 897 |
| coagulopathySignal | 11 | 46.6 | 26.1 | 447 |
| multiple organ dysfunction syndromeSignal | 14 | 34.9 | 20.9 | 428 |
| lactic acidosisSignal | 11 | 24.0 | 13.4 | 220 |
| pancreatitisSignal | 11 | 14.7 | 8.2 | 127 |
| thrombocytopeniaSignal | 18 | 11.4 | 7.3 | 161 |
| off label useSignal | 98 | 7.9 | 6.7 | 609 |
| drug intoleranceSignal | 10 | 7.3 | 4.0 | 49 |
| product use in unapproved indicationSignal | 15 | 4.3 | 2.6 | 35 |
| condition aggravatedSignal | 12 | 2.8 | 1.6 | 12 |
| drug ineffective | 33 | 1.8 | 1.3 | 11 |
| diarrhoea | 14 | 1.5 | 0.9 | 2 |
| nausea | 15 | 1.3 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.